



# Ontario Health

## Cancer Care Ontario

Guideline 16-3 version 3

A Quality Initiative of the  
Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care  
Ontario)

### Safe Handling of Hazardous Drugs

*K. Kennedy, K. Vu, N. Coakley, J. Daley-Morris, L. Forbes, R. Hartzell, D. Lessels, and the  
Nursing Guideline Development Group*

**Report Date: September 26, 2022**

For information about this document, please contact Kardi Kennedy and Kathy Vu, the lead authors, through the PEBC at:  
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: [ccopgi@mcmaster.ca](mailto:ccopgi@mcmaster.ca)

For information about the PEBC and the most current version of all reports, please visit the OH (CCO) website at <https://www.cancercareontario.ca/en/guidelines-advice> or contact the PEBC office at:

Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: [ccopgi@mcmaster.ca](mailto:ccopgi@mcmaster.ca)

**PEBC Report Citation (Vancouver Style):** Kennedy K, Vu K, Coakley N, Daley-Morris J, Forbes L, Hartzell R, Lessels D, and the Nursing Guideline Development Group. Safe Handling of Hazardous Drugs. Toronto (ON): Ontario Health (Cancer Care Ontario); 2022 September 26. Program in Evidence-Based Care Guideline No.: 16-3 V3.

#### **PUBLICATIONS RELATED TO THIS REPORT**

A practice guideline has been published in the peer-reviewed Journal of Oncology Pharmacy Practice <https://journals.sagepub.com/doi/full/10.1177/10781552221135121>

Kennedy K, Vu K, Coakley N, et al. Safe handling of hazardous drugs. Journal of Oncology Pharmacy Practice. 2022;0(0). doi:10.1177/10781552221135121

#### *Copyright*

This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express written permission of Ontario Health (Cancer Care Ontario). Ontario Health (Cancer Care Ontario) reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

#### *Disclaimer*

Care has been taken in the preparation of the information contained in this report. Nevertheless, any person seeking to consult the report or apply its recommendations is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinician. Ontario Health (Cancer Care Ontario) makes no representations or guarantees of any kind whatsoever regarding the report content or its use or application and disclaims any responsibility for its use or application in any way.

# Safe Handling of Hazardous Drugs

## Section 1: Recommendations

### RECOMMENDATIONS

#### Recommendation 1: General Measures

##### **Committee Responsible for Policy and Procedures for Hazardous Drugs**

It is strongly recommended that all institutions administering hazardous drugs form such a committee. It is also strongly recommended that this committee include, but not be limited to, representatives from various departments and services such as: occupational health and safety, joint health and safety committee, pharmacy, nursing, medical oncology (physician), environmental services, risk management, and a patient representative.

This committee would be responsible for clear processes of developing, reviewing, and revising policies and procedures related to hazardous drugs. A risk assessment and gap analysis should be routinely conducted to identify gaps and to inform policies and procedures. In addition, this committee is responsible for ensuring that there is a process in place for orientation and ongoing education for the identified target population.

This committee is responsible for implementation and follow-up of the Risk Prevention Management Program related to the use of hazardous drugs.

##### **Continuing Education and Orientation Program**

It is legislated that initial and ongoing hospital-approved education be provided to all staff involved with hazardous drugs throughout the medication circuit including safe handling and spill or leak management (6). It is strongly recommended that all staff have initial and ongoing training related to best practice standards in place at the time.

It is legislated that there is documentation that annual training of safe handling of hazardous drugs has occurred (6). This should be documented by the institution's Committee Responsible for Policy and Procedures for Hazardous Drugs

##### **Identification and Safety**

It is strongly recommended that each institution maintain a list of hazardous drugs that are used in their facility, that is reviewed regularly, when policy is updated, and whenever a new agent or dosage is used (7).

It is legislated that hazardous drugs and their waste be properly identified with the symbol capital "C" and, under it, the words "CYTOTOXIC/CYTOTOXIQUE" in capital letters (8, 9). It is legislated that all hazardous waste under the Ministry of Environment, Conservation and Parks regulation (guideline C-4) include bilingual wording and both the words and the symbol appear on a dark grey rectangle (8, 9). Other countries may have their own systems for labeling and should be adhered to.



### **Purchasing of Drugs**

When purchasing hazardous drugs, it is strongly recommended that institutions consider vendors that include safe handling measures such as pre-wiped or protective containers, or smaller receptacles to decrease volume of potential spills.

### **Spills Kit**

It is strongly recommended that a spill-management kit be available in all areas where hazardous drugs are stored, transported, handled, and administered (10).

### **Precautionary Reassignment**

It is strongly recommended that all staff be fully informed of the potential reproductive hazards of hazardous drugs (11).

It is strongly recommended that the facility consider alternative duties for staff who are pregnant, breast feeding or actively trying to conceive.

## **Recommendation 2: PPE**

It is legislated that a worker work in compliance with the Occupational Health and Safety Act and regulations and use or wear the equipment, protective devices, or clothing that the employer requires to be used (1).

It is legislated that the appropriate PPE for the task (as described in Table 2-1) be worn throughout the medication circuit (1). It is the employer's responsibility to provide the necessary protective equipment and training on how to use the equipment.

### **Gloves**

The gloves used to handle hazardous drugs are strongly recommended to comply with ASTM standard D-6978-(05)-13 and be powder free (12). Gloves are recommended to be nitrile, polyurethane, neoprene, or latex (12). Latex is a known allergen; therefore, it is strongly recommended that this be taken into consideration for glove selection. It is strongly recommended that vinyl gloves not be used (13). It is strongly recommended that the frequency of glove changes be adjusted according to the level of exposure at each step in the medication circuit. For example, when administering reconstituted medications, it is strongly recommended that workers change gloves immediately if torn, punctured, or visibly contaminated with a hazardous drug, and to ensure following Routine Practices (14). Gloves should be changed every 30 minutes unless otherwise recommended by the manufacturer's documentation (7, 10). It is strongly recommended that great care be taken in the removal of gloves to not contaminate the skin. When two pairs of gloves are required, put on the first pair before putting on the gown. See Appendix 4 for the donning and doffing of one pair of gloves and Appendix 5 for the donning and doffing of two pairs of gloves.

**Gown**

It is strongly recommended that the gowns used for handling hazardous drugs be disposable, made of lint-free, low-permeability fabric, have long sleeves with tight-fitting cuffs and fasten in the back. Gowns need to be changed in the event of contamination, spillage, rips, and at the end of the procedure. It is strongly recommended that the supplier be able to certify that the gown protects against hazardous drugs (10).

For medication preparation and administration, gowns need to be changed halfway through a shift or every 3 and a half hours (7, 10).

It is strongly recommended that care be taken to avoid contamination of the hands by avoiding touching the outside of the gown when removing the gown.

**Facial Protection**

Surgical/procedure masks are required while handling and preparing medications in a BSC and, in this instance, are worn to prevent microbial contamination of the sterile field.

Goggles and a face shield or full face-piece respirator should be worn when there is a risk of spills or splashes of hazardous drugs or hazardous waste materials when working outside of a BSC such as administration of hazardous drugs in the surgical suite, working at or above eye level, or cleaning a spill (7, 10).

Head and hair coverings (including beard and moustache, if applicable), and sleeve covers provide protection from contact with hazardous drug residue. Disposable sleeve covers may be used to protect areas of the arm that may come in contact with hazardous materials. Disposable sleeve covers made of polyethylene-coated polypropylene or other laminate materials offer better protection than those made of uncoated materials (7).

It is strongly recommended that full-facial protection be worn whenever there is a risk of splashing (e.g., during certain drug administration procedures). The use of a full-facial shield is preferred. If goggles are used, they need to be worn in conjunction with a fluid-resistant mask. For further information, see *Canadian Standard Association (CSA) standard Z94.3-07 - Eye and Face Protectors* (15). Eyeglasses alone or safety glasses with side shields do not protect the eyes adequately from splashes. Face shields in combination with goggles provide a full range of protection against splashes to the face and eyes. Face shields alone do not provide full eye and face protection (7).

**Respiratory Protection Devices**

It is strongly recommended that fit-tested respirators such as NIOSH-certified N95 or N100 be used when there is a risk that airborne powder or aerosol will be generated. It is legislated that respirators be used in accordance with a respiratory protection program such as that outlined in *CSA Standard Z94.4-18 "Selection, Use and Care of Respirators"* (16).

**Caps**

Caps are only required in the sterile preparation room and are worn to prevent microbial contamination of the sterile field.

**Shoe Covers**

Disposable shoe covers are worn to prevent contamination of the healthcare workers' shoes, and it is strongly recommended that they be worn when in the sterile preparation room or in

the event of a spill. It is strongly recommended that shoe covers be removed immediately when leaving the sterile prep room to avoid contamination of other areas. When compounding hazardous drugs, a second pair of shoe covers must be donned before entering the Containment Secondary Engineering Control (C-SEC) and doffed when exiting the C-SEC (7, 10).

**Table 2-1. Personal protective equipment to be worn throughout the medication circuit**

Medication circuit steps	Gloves	Gown	RPD	Facial protection	Cap	Shoe covers
Unpacking and cleaning	✓ (2 pairs)	✓	✓ (Only if unpacking hazardous drugs that are not contained in plastic until assessment of the packaging integrity can be made)			
Sterile preparations	✓ (2 pairs)	✓		✓	✓	✓ (2 pairs)
Non-sterile preparations: - Counting of solid oral forms	✓ (1 pair)	✓				✓
Non-sterile preparations: -Preparing creams, ointments, oral solutions and crushing tablets	✓ (2 pairs)	✓			✓	✓ (2 pairs)
Routes of administration (intravenous, subcutaneous, intramuscular, intravesical, intraperitoneal, intrathecal, liquid oral)	✓ (2 pairs)	✓		✓ (If risk of splashing, e.g., bladder installation or NG, G, or J tube)		
Solid oral administration (tablets)*	✓ (1 pair)					
Topical administration (creams, ointments)	✓ (2 pairs)	✓		✓ (If risk of splashing)		

Medication circuit steps	Gloves	Gown	RPD	Facial protection	Cap	Shoe covers
Aerosolized administration (e.g., ribavirin, pentamidine) <sup>†</sup>	✓ (2 pairs)	✓	✓	✓ (If risk of splashing)		
Patient care	✓ (1 pair)	✓ (When at risk for exposure for bodily fluids)		✓ (If risk of splashing, e.g., disposal of bodily fluids)		
Management of extravasation	✓ (2 pairs)	✓		✓ (If risk of splashing)		
Handling of contaminated bedding on the wards	✓ (2 pairs)	✓				
Waste management (collection and transport)	✓ (2 pairs)					
Spill or damaged or broken container	✓ (2 pairs)	✓	✓ (If suspicion of powder or aerosolization is generated)	✓		✓ (If on the floor)
Cleaning of sterile preparation room and airlock	✓ (2 pairs)	✓			✓	✓ (2 pairs)
Cleaning of preparation cabinets (hoods)	✓ (2 pairs)	✓	✓	✓	✓	✓
Cleaning of other oncology pharmacy rooms and care units/clinics	✓ (1 pair)	✓				

Abbreviations: G = gastric tube, J = jejunostomy tube, NG = nasal gastric tube, RPD= respiratory protection device.

\*Although the risk of contamination with oral medications is minimal, the Working Group members believe that consistency of practice for any handling of hazardous drugs is of primary importance, and the preference is to wear a standard chemotherapy glove.

<sup>†</sup> Although hazardous, they are not cytotoxic

### Recommendation 3: Receiving and Transport

#### Handling Hazardous Drug Delivery Containers

It is strongly recommended that all receiving-dock workers receive training in the proper handling of hazardous drugs. It is strongly recommended that the receiving-dock workers check the integrity of the external packaging upon receipt; in the event of breakage or a damaged parcel likely to cause a spill, apply the Spill Protocol from your institution.

It is strongly recommended that delivery containers be taken immediately to the Pharmacy Department by the receiving-dock workers or the distributor.

It is strongly recommended that the receiving-dock or storeroom workers not open the delivery containers. It is strongly recommended that the delivery containers be handled with care to avoid breakage of the hazardous drug containers and not be left unattended in a corridor. Only trained workers (e.g., pharmacy technicians) are to proceed with the unpacking and subsequent steps.

#### **Damaged Containers/Spill**

It is strongly recommended that damaged containers be handled like spills. It is strongly recommended that the manufacturer or distributor be notified if the container is received in a damaged state. To limit exposure, it is strongly recommended that a damaged container not be returned to the manufacturer or distributor unless they require it returned. The damaged container will need to be returned in an impervious box. Notify the pharmacy if any damaged containers are suspected (7).

See *Recommendation 10: Management of Waste, Accidental Exposure, Spills and Returns*.

#### **Recommendation 4: Unpacking and Storage**

Packaging can have high levels of contamination. It is strongly recommended that there be an unpacking area in the pharmacy limiting exposure risks. It is strongly recommended that the unpacking area be a separate dedicated space, separate from eating areas, and preferably a separate room. It is regulated that there be adequate ventilation in the area, negative pressure, and preferably vented to the outside. It is strongly recommended that there be a receptacle for hazardous waste in the unpacking area, for the disposal of secondary packaging (6, 10, 17).

It is strongly recommended that workers at risk of exposure wear a protective gown and two (2) pairs of gloves when unpacking and cleaning hazardous drugs, from the opening of the external packaging to the placing of the secondary and/or primary packaging in their storage space. It is strongly recommended that workers check the integrity of all packaging at every step of the unpacking process. In the event of breakage or leaking, it is strongly recommended that the damaged contents be treated as a spill. It is strongly recommended that the primary and or secondary packaging be cleaned prior to being placed in storage.

It is strongly recommended that a regular cleaning protocol be in place either at this stage or prior to storage in the clean room. It is strongly recommended that all drug containers be cleaned to reduce external contamination. An example is the use of pre-moistened towelettes. It is important to ensure that the procedure does not damage the container or interfere with the reading of the label. It is also important to ensure that any product that is used will not further contaminate the product or work environment. However, it is strongly recommended that this procedure not increase the risk of incidents/accidents due to damage to the hazardous drug container or label.

It is strongly recommended that procedures be in place to minimize the risk of contamination of surfaces during the cleaning of vials (e.g., use of a disposable, plastic-backed, absorbent pad). It is strongly recommended that all surfaces be cleaned when the task is complete.

Establish a dedicated negative-pressure storage area for hazardous drugs that minimizes the risk of contamination (10).



When removing or transporting drugs out of the storage area, it is strongly recommended that one pair of gloves and a gown be worn and a spill kit be readily available.

### **Recommendation 5: Planning the Oncology Pharmacy**

It is strongly recommended that the oncology pharmacy be in compliance with relevant guidelines from the Canadian Society of Hospital Pharmacists and Accreditation Canada standards. While the specific details of oncology pharmacy planning are beyond the scope of this document, details and some important considerations may be found in the National Association of Pharmacy Regulatory Authorities (NAPRA) guideline and *CSA document CSA Z8000-11* (5, 10, 18).

It is strongly recommended that special requirements for heating, ventilation, and air-conditioning systems in healthcare facilities be taken into consideration (10, 17).

A class II type B BSC is required with preference for the type B2 because it ensures that there is no recirculation of air within the cabinet (4, (5, 10).

There is emerging evidence suggesting some robotic devices that prepare hazardous drugs improve the accuracy of medication preparation and reduce potentially harmful staff safety events. Further studies are required to establish the cost effectiveness of these robotic implementations. Each healthcare facility will need to assess the need for such devices in their environment (5,19-21, 31).

It is strongly recommended that all mixing, and preparation of administration sets with a hazardous drug be performed in one centralized area in a specially designated class II type B BSC (17) that:

- a. is exhausted through a HEPA filter to the outside atmosphere in a manner that prevents recirculation into any inside area;
- b. has exhaust and ventilation systems that remain in operation for a sufficient period of time to ensure that no contaminants escape from the BSC into the workplace; and
- c. is equipped with a continuous monitoring device to permit confirmation of adequate airflow and cabinet performance.

It is recommended that airlocks be considered if there are particular concerns about the propagation of airborne hazardous drugs.

It is strongly recommended that priming of administration sets be prepared in the manner mentioned above.

It is strongly recommended that the layout allow and facilitate the unimpeded cleaning of all surfaces (walls, floors, ceilings, doors, diffusers, windows). It is strongly recommended that the furniture and equipment in the sterile preparation room be kept to a bare minimum. It is strongly recommended that there be a visual link; for example, a sealed window and a way to communicate between the sterile preparation room and the pharmacy, to view the work in progress. It is strongly recommended that access to the sterile room be limited to

trained and authorized workers (10). A pass-through window can be installed to minimize the risk of contamination when transferring products into and out of the clean room. The pass-through should be equipped with an interlocking system or procedure that prevents both doors from being open at the same time (10)

Limit worker traffic, particularly near unpacking and storage areas (to avoid accidental breakage) and near preparation cabinets (to avoid interfering with their proper operation).

It is legislated that the facilities include an emergency eyewash that may or may not be hooked up to the airlock sink (1). As a minimum, it is strongly recommended that emergency eyewash be able to provide 15 minutes of flushing to both eyes (22). It is strongly recommended that a full shower be accessible nearby (e.g., in the oncology units/clinics).

Closed system drug-transfer devices (e.g., PhaSeal®) are not a substitute for class II type B BSC. There is evidence from studies (23-30, 32-42, 57,58) that closed system drug-transfer devices can reduce contamination during preparation and increase or extend the beyond use date of a drug. Further emerging evidence suggests that when these devices are not used as specified, they could become open to the environment. Further research is needed to evaluate this possibility.

In the non-sterile drug preparation process (e.g., oral preparations), it is strongly recommended that the same level of worker protection be adhered to.

#### **Pharmacy Policies and Procedures**

Establish policies and procedures regarding preventive maintenance, monitoring, certification and the optimal use of facilities and equipment (45).

### **Recommendation 6: Hazardous Drug Preparation**

The following recommendations apply but are not limited to the preparation of all hazardous medications including parenteral, oral, and topical, both sterile and non-sterile preparations. It is strongly recommended that policies and procedures include the use of appropriate PPE, the equipment for preparation including appropriate ventilation, and other automated equipment for packaging and a dedicated work area.

#### **PPE**

It is strongly recommended that workers (pharmacists or pharmacy technicians) wear a cap, surgical/procedure mask, shoe covers, a protective gown and two (2) pairs of gloves (see Table 2-1) to make sterile preparations of hazardous drugs in preparation cabinets.

#### **Organization of the Work**

Organize the work to limit microbial and environmental contamination.

For both sterile and non-sterile preparations, it is strongly recommended that workers cover the work surface with a disposable, absorbent, sterile, plastic-backed pad to absorb any liquid contamination that may occur during handling. It is strongly recommended that the pad not cover the front and rear grilles of the preparation cabinet. It is strongly recommended that it be changed after 3.5 hours of continuous work or for a new batch of

preparations (e.g., a set of vials of a given drug) or in the event of a spill or contamination (13). It is legislated that the pad be disposed of in a hazardous waste receptacle (7, 9).

Limit the quantity of supplies and hazardous drugs in the cabinet, to avoid adversely affecting the laminar flow and to facilitate regular cleaning of the work surface. Place the sterile products in the centre and the non-sterile products (e.g., waste receptacle) along the sides of the cabinet.

### **Removal of Packaging**

Remove the packaging, when applicable, and clean all the drug containers before taking them into the preparation cabinet. For sterile preparations, adhere to aseptic technique for sterility.

### **Handling Techniques**

Use handling techniques that limit the risk of injury or accidental exposure. Direct CSTD spikes can be used to connect the hazardous medication bag directly to the tubing if spiking must occur at the bedside. When this adaptor is not used, IV bags containing hazardous drugs should only be spiked in a BSC to prevent exposure.

### **Preparation, Priming and Removing Air from the Tubing**

It is strongly recommended that hazardous drugs be reconstituted in the pharmacy environment as described above. It is strongly recommended that the drug containers not be overfilled to avoid compromising the integrity of the container. It is strongly recommended that the techniques used for priming and removal of air minimize the exposure risks. It is recommended to only remove air from an IV tubing that does not contain a solution with a hazardous drug(s). It is strongly recommended that IV tubing is primed and air removed in the pharmacy, prior to adding the hazardous drug(s) to the infusion solution. Glass containers are not recommended due to increased risk of breakage and exposure.

### **Labeling and Final Packaging**

It is legislated that hazardous drugs be labeled to inform those handling these preparations of the nature of the drugs and the precautions to be taken. It is legislated that hazardous drugs display the “Cytotoxic” hazard symbol or the word “Cytotoxic” (8, 9).

It is strongly recommended that the outside surface of the hazardous drug containers (e.g., syringes, infusion bags, tubing) in the preparation cabinet be cleaned in the cabinet.

Place each hazardous drug container (e.g., syringe, bag), as well as the administration supplies (e.g., tubing), in a clear, leak-proof plastic bag (e.g., Ziploc® type) to facilitate identification by the nurse without having to remove the container from the bag.

Following final verification in the pharmacy, it is strongly recommended that the plastic bags containing the hazardous drugs be placed in a rigid *transport container* (ideally opaque), properly identified with the “Cytotoxic” hazard symbol (7, 10).

### **Waste**

It is strongly recommended that everything that comes out of the cabinet be wiped clean.

It is strongly recommended that all contaminated waste be disposed of in the chemotherapy waste stream.

## Recommendation 7: Transport and Storage Following Preparation

### On-site Transport of Hazardous Drugs

Transport hazardous drugs using a method that will prevent contamination of the environment in the event of breakage.

It is strongly recommended that hazardous drugs be placed in a closed, single-use leak-proof plastic bag (e.g., Ziploc® type).

It is strongly recommended that transport of the hazardous drug in a single-use closed, leak-proof plastic bag from the pharmacy to an area not adjacent to the preparation area (e.g., care unit, outpatient clinic), be done in a rigid, shock-resistant, leak-proof container made of a material that can be easily cleaned and decontaminated in the event of a drug leak (5). It is strongly recommended that the bottom be covered with an absorbent, plastic-backed cloth.

It is legislated that the transport container be identified with the “Cytotoxic” hazard symbol and be cleaned regularly (8, 9). This container should be cleaned according to the protocol outlined by a committee responsible for hazardous drug handling.

It is strongly recommended that mechanical transport systems, such as pneumatic tubes, not be used because of the stress they put on the contents, and the whole transport system would be compromised if a leak occurred (5, 7).

It is strongly recommended that prepared medications be stored in a designated area prior to administration. It is strongly recommended that this area be cleaned regularly.

### Off-site Shipping and Transport of Hazardous Drugs

Establish policies and procedures regarding the shipping of hazardous drugs (46).

In the event that hazardous drugs are shipped off-site (e.g., from one institution to another), it is strongly recommended that they be packed separately from other drugs, according to the recommendations from the manufacturer and distributor. It is strongly recommended that pharmacy be consulted in the packaging of hazardous drugs.

It is strongly recommended that hazardous drugs be packed in a double plastic bag and placed in a box that is properly identified with the “Cytotoxic” hazard symbol. If necessary, immobilize the drug with packing (5) material. It is legislated that the “Cytotoxic” hazard symbol be visible on the outside of the delivery (8) container. It is strongly recommended that reusable delivery containers be cleaned regularly.

Ensure that the courier company will handle hazardous drugs.

## Recommendation 8: Drug Administration

It is strongly recommended that safe handling and administration techniques be used to minimize possible exposure to individuals and the environment when administering hazardous drugs.

- It is legislated that appropriate PPE be made available to all healthcare workers and be worn as prescribed by the employer (Table 2-1) (1).
- It is strongly recommended that Luer lock connectors and needleless administration systems be used to administer any IV medications.
- Closed system drug-transfer devices may offer additional protection.
- It is strongly recommended that disposable plastic-backed absorbent pads be used over work surfaces and placed under tubing or bag connections and ports when attaching any tubing, bag or syringe that has been exposed to a hazardous drug.
- Unless a closed system is used, never disconnect tubing from hazardous drug bags. Discard bag with attached tubing into an appropriate waste container as a single unit.
- It is legislated that safety engineered needles be used as per Needle Safety Regulation 474/07 made under the Occupation Health and Safety Act Labour, 2010 (47). Do not purge air from the needle before administration.
- It is strongly recommended that oral hazardous drugs be handled in a manner that avoids skin contact, liberation of aerosols or powdered medicine into the air, and cross-contamination with other (48) medicines.
- It is strongly recommended that solid oral preparations (tablets) of hazardous drugs be crushed or cut within the BSC. If patients are unable to take in the solid format, it is strongly recommended that the pharmacy provide these drugs in an oral syringe or dissolve and dose container, in a ready-to-administer, liquid oral form.
- It is strongly recommended that application of topical hazardous drugs be done using appropriate PPE and in a way that prevents contamination of the environment. Between applications, it is strongly recommended that the hazardous medication (i.e., tube or jar) be kept in a safe container (i.e., Ziploc®) and in a secure place that prevents contamination of the surrounding environment.
- With any intravesical administration, e.g., bladder instillation, ensure there are detailed procedures in place to avoid risks of splashing.
- Use caution when administering intrathecal hazardous drugs, as there is risk of splashing due to increased intrathecal pressures. A closed system (i.e., Luer lock) should be used when possible.

### **Recommendation 9: Home Care**

#### **Home Care of Patients who Have Received Hazardous Drugs**

It is strongly recommended that all hazardous drug preparations be compounded in pharmacies meeting the requirements for hazardous drug preparation (5).

It is strongly recommended that hazardous drugs be transported, administered and disposed of by individuals who have received appropriate training. It is strongly recommended that hazardous drug transport containers are not reused by patients for domestic purposes, which may expose the family to cytotoxic drugs (e.g., toy box, sewing basket, etc.).

It is legislated that the healthcare provider who administers hazardous drugs in the home wear PPE as outlined in Table 2-1 (1).

It is strongly recommended that healthcare providers follow the same recommendations outlined in *Recommendation 8 - Drug Administration*

It is strongly recommended that a spill kit be readily available in the home in case of accidental spills.

It is strongly recommended that patients be informed of and be provided with written instructions and PPE for the safe handling of hazardous drugs.

It is strongly recommended that contact information be provided for home care patients who require assistance with safe handling of hazardous.

#### **Hazardous Drug Waste in the Home**

It is strongly recommended that the institution have a clear process to address the issue of hazardous waste from patients in their homes, in compliance with municipal or local hazardous waste rules. It is strongly recommended that this process include patient and caregiver education.

It is strongly recommended that caregiving staff provide the patients/caregivers involved in administering cytotoxic drugs in the home with a process for appropriate disposal of hazardous waste, including leftover drugs.

### **Recommendation 10: Management of Waste**

#### **Bodily Fluid Waste**

It is strongly recommended that workers who handle the biological fluids, excreta, contaminated bedding, and soiled equipment of patients who have received hazardous drugs wear two (2) pairs of gloves and a protective gown. It is strongly recommended that face protection be worn when there is a risk of splashing.

#### **Cytotoxic Drug Waste**

Establish policies and procedures as per provincial legislation regarding hazardous waste management.

The term “hazardous waste” includes any material that comes into contact with hazardous drugs during their storage, handling, preparation, administration and disposal (e.g., packaging material, protective equipment, preparation supplies, such as syringes, tubing, drug bags; soiled disposable incontinent briefs of patients who have received hazardous drugs during the previous 48 hours or longer depending on the drug [e.g., it is known that cyclophosphamide may persist for several days]; hood pre-filters and HEPA filters, etc.).

It is legislated that hazardous waste be placed in a waste container clearly identified with the “Cytotoxic” hazard symbol. It is legislated that hazardous waste be disposed of in the appropriate containers (9).

It is legislated that sharps be placed in rigid containers with a leak proof lid; CSA standard Z316.6--07 specifies the use of the colour red for the rigid containers (49). If the containers are another colour, follow the instructions of the company ensuring the final disposal (9).

It is strongly recommended that other waste (soft items, such as tubing, protective equipment, etc.) be placed in leak-proof and tear-resistant containers, identified with the “Cytotoxic” hazard symbol (7).

For final disposal outside the institution, it is legislated that all hazardous waste be in a rigid, leak proof, container identified with the “Cytotoxic” hazard symbol and scheduled for transport outside the institution (9).

It is legislated that any excess fluid from hazardous drugs (e.g., drug loss) be disposed of in a sealed container and placed in a rigid container, the bottom of which is to be covered with an absorbent pad. This rigid container will be handled like other hazardous waste (9).

It is recommended that disposable/incontinent briefs soiled by patients who have received hazardous drugs be placed in a hazardous waste container.

It is legislated that hazardous waste be incinerated according to ministry guidelines (9, 50).

It is legislated that hazardous waste not be disposed of in the receptacles used for infectious biomedical waste (which may be autoclaved and then sent to a landfill site) (9).

It is legislated that every area where hazardous drugs are handled will have an appropriate hazardous waste receptacle as close as possible to the work area (9).

The lids of hazardous drug receptacles must remain closed, except when depositing waste. Bins with foot pedals and lids, which lock automatically when full, are recommended to minimize exposure.

It is strongly recommended that workers be careful to avoid contaminating the outside of the receptacle when depositing waste.

It is legislated that the transport of hazardous waste receptacles be assigned to properly trained workers (6).

It is strongly recommended that workers who handle hazardous waste receptacles wear two pairs of disposable gloves and have a spill kit at their disposal. It is strongly recommended that the waste go through as few care units, public areas and areas containing food or linens as possible.

It is legislated that the final storage areas for hazardous waste receptacles be secure. Refer to Ontario storage (8, 9) requirements.

#### **Recommendation 11: Accidental Exposure**

Be aware of any mandatory reporting requirements under the Occupational Health and Safety Act and report requirements to Workplace Safety and Insurance Board (WSIB) (6).

Establish policies and procedures regarding accidental worker exposure.

If a hazardous drug accidentally comes into contact with a worker's skin or clothing, it is strongly recommended that the worker immediately remove the contaminated clothing and thoroughly wash the skin of the affected area with soap and water and continue to rinse for 15 minutes. If appropriate, it is strongly recommended that the contaminated worker take a shower. It is strongly recommended that a deluge shower be made available in the vicinity (e.g., in the oncology clinics/units). It is strongly recommended that all contaminated clothing be discarded in hazardous waste. Workers should seek medical attention after exposure.

If a hazardous drug comes into contact with a worker's eyes, it is strongly recommended that the worker flush their eyes at an eye wash station. Alternatively, it is recommended that the workers use an isotonic solution to flush their eyes (e.g., sterile NaCl 0.9%). It is strongly recommended that eyes be flushed for at least 15 minutes (22). It is strongly recommended that if contact lenses are worn, they be removed immediately prior to flushing. Workers should seek medical attention after eye exposure.

In the event of a needlestick or sharps injury, let the wound bleed freely. Under running water, gently and thoroughly wash the area with soap. Contact Occupational Health. Ensure that facility policies for needlestick or sharps injury are followed including completion of an incident report and reporting to WSIB if indicated.

#### **Recommendation 12: Spills Management**

It is strongly recommended that the facility develop policies and procedures for spills management that take into account the types of spills (i.e., amount, location, concentration, powder vs. liquid, etc.), incidence reporting, surveillance of spills and restocking of equipment.

All staff working in environments where hazardous drugs are handled should be trained in the use of a spill kit.

It is strongly recommended that a spill kit be readily available in all areas where hazardous drugs are stored, transported handled and administered.

It is strongly recommended that a spill kit be readily available in the home in case of accidental spills, but institutions must ensure patients, or their caregivers are trained on the use of the spill kit and PPE.

It is legislated that disposable items from the clean-up of spills be placed in the hazardous waste receptacle (9). Non-disposable items should be thoroughly cleaned and decontaminated.

The area of the spill should be decontaminated deactivated and disinfected (10).

Most spills can be contained and managed by trained staff (e.g., leaking IV tubing).

When a spill is not contained or easily managed (e.g., exposure to large volume of fluid that is a risk to the environment or a large crate of vials filled with powder broken in the receiving area), it is strongly recommended that a Code Brown or equivalent be called.



### **Recommendation 13: Environmental Cleaning**

Establish environmental cleaning policies and procedures for all surfaces where contact with hazardous drugs may occur. Areas should be decontaminated deactivated and disinfected following legislative procedures. Examples may include unpacking and storage, preparation, administration, and disposal areas. Pharmacy counters are among the most contaminated surfaces (5, 7, 10).

It is strongly recommended that cleaning of the BSC be performed by trained personnel following manufacturer's and NAPRA's guidelines (7, 10).

#### **Use of Pumps to Administer Hazardous Drugs**

Make sure there is an appropriate policy to clean and inspect the equipment between uses.

#### **Laundry**

Ensure the facility complies with the Occupational Health and Safety Act - Ontario Regulation for Health Care and Residential Facilities (6). Contaminated items should be placed in sealable bags and washed separately from other items (5).

### **Recommendation 14: Medical Surveillance and Environmental Monitoring**

#### **Medical Surveillance**

Methods used to investigate potential health effects of exposure to hazardous drugs are inconclusive and difficult to interpret. The ideal test should meet several requirements – it should be sensitive, specific, quantitative, rapid, and reproducible. Importantly, the procedures for taking a sample should be non-invasive and should not cause unnecessary duress or anxiety to the individual (7).

Unfortunately, there is currently no suitable test to meet these requirements. Therefore, there is conflicting information and opinion about the value of routine biological monitoring for employees handling hazardous drugs.

Employers do have a responsibility to ensure that they remain aware of and apply any future developments for monitoring the health of employees in the handling of hazardous drugs.

The panel supports further research to determine if there are adverse health effects that result from exposure to hazardous drugs.

Adherence to agreed standard operating procedures with sufficient initial and regular ongoing training in safe handling/administration is paramount to reducing potential for exposure and risk.

There is evidence in the literature of a higher rate of spontaneous abortion among women working in roles that expose them to hazardous drugs (51, 52). There are no other identified medical conditions known to result from chronic exposure of healthcare workers to hazardous drugs, no exposure limits set for hazardous drugs, and no standards for interpretation of test results of exposed healthcare workers to enable meaningful interpretation or action based on biological monitoring results.

**Environmental Monitoring**

It is recommended that the facility implement an environmental monitoring program. Surface testing would audit contamination of the environment (e.g., pharmacy counters, patient bedside tables) and provide a quality indicator of cleaning effectiveness and adherence to recommended work practices (5).